108-14 72nd Ave, Second floor — Forest Hills, New York

108-14 72nd Ave, Second floor is a clinical research site located in Forest Hills, New York, United States 11375.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

108-14 72nd Ave, Second floor has participated in 1 clinical trials.

Therapeutic areas: Parkinson's Disease.

Sponsors: Neuraltus Pharmaceuticals, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Forest Hills

Browse all research sites in New York · View every site in Forest Hills

• New York University Medical Center
• St. Luke's Roosevelt Hospital
• Forest Hills Dermatology Group
• Northwell Health Physicians Partners Radiation Medicine at Queens
• Regeneron Investigational Site
• Novartis Investigative Site
• Research Site
• GSK Investigational Site
• Study Site 375
• Research Facility
• SPARC Site 4
• Galderma Investigational Site 8828

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for 108-14 72nd Ave, Second floor?

108-14 72nd Ave, Second floor has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has 108-14 72nd Ave, Second floor conducted?

108-14 72nd Ave, Second floor has 1 clinical trials on record. Their work covers Parkinson's Disease.

Is 108-14 72nd Ave, Second floor accredited by Crixeo Clinical Trials?

108-14 72nd Ave, Second floor has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about 108-14 72nd Ave, Second floor?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.